Scarica l'app Stockscreener
0.9155
0.59%
-0.0054
Dopo l'orario di chiusura:
.96
0.0445
+4.86%
Precedente Chiudi:
$0.9209
Aprire:
$0.93
Volume 24 ore:
2.75M
Relative Volume:
0.78
Capitalizzazione di mercato:
$156.31M
Reddito:
$126.33M
Utile/perdita netta:
$-82.68M
Rapporto P/E:
-0.7383
EPS:
-1.24
Flusso di cassa netto:
$-79.98M
1 W Prestazione:
+4.20%
1M Prestazione:
+12.48%
6M Prestazione:
+21.82%
1 anno Prestazione:
-14.44%
Intervallo 1D:
$0.9154
$0.962
Intervallo di 1 settimana:
$0.85
$0.9738
Portata 52W:
$0.54
$2.05
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Confronta MCRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.9155 | 156.31M | 126.33M | -82.68M | -79.98M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times
Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online
Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance
MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times
FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire
Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria
Seres Therapeutics Q3 2024 Earnings Preview - MSN
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com
Seres Therapeutics chief legal officer sells shares worth $474 By Investing.com - Investing.com Australia
Seres Therapeutics executive sells shares worth $397 - Investing.com
Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com Canada
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance
Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... By GuruFocus - Investing.com Canada
Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks
Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks
Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks
Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register
Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times
Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan
Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia
Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 - Investing.com India
Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India
Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):